First-Line PD-1 Inhibitor-Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta-Analysis of Phase III Trials. (PubMed, Cancer Rep (Hoboken)) - Sep 8, 2026 - "First-line PD-1 inhibitor-based therapy confers a robust OS benefit in advanced/metastatic ESCC and supports chemoimmunotherapy as a contemporary standard of care. Remaining uncertainties relate mainly to biomarker-negative disease, assay heterogeneity, and cross-trial differences in chemotherapy backbone and geographic composition."
Clinical • IO biomarker • Journal • P3 data • Retrospective data • Review • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • PD-L1
|
|
Björn Erik Ole Jensen; Christoph Roderburg; Edwin Bölke; Guangyu Lu; Ilyas Gencer; Johannes C Fischer; Muemtaz Koeksal; Torsten Feldt; Vincent Rothweiler; Wilfried Budach; Wolfram Trudo Knoefel
|